Current Hematologic Malignancy Reports

, Volume 13, Issue 6, pp 555–569 | Cite as

Combining Biology and Chemistry for a New Take on Chemotherapy: Antibody-Drug Conjugates in Hematologic Malignancies

  • Helen Ma
  • Ahmed SawasEmail author
B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (J Amengual, Section Editor)
Part of the following topical collections:
  1. Topical Collection on B-cell NHL, T-cell NHL, and Hodgkin Lymphoma


Purpose of Review

This review is about the antibody-drug conjugate (ADC), a form of drug delivery consisting of a monoclonal antibody, linker, and cytotoxic payload. We summarize the history of ADC development, highlighting the three FDA-approved ADCs currently available.

Recent Findings

Gemtuzumab ozogamicin is a CD33-targeted ADC linked to calicheamicin. It is approved for CD33+ AML in the first line or the relapsed or refractory (R/R) setting. Brentuximab vedotin is a CD30-targeted ADC bound to MMAE. It is approved for the treatment of certain R/R CD30+ lymphomas. Recently, it has been approved for first line therapy with chemotherapy in advanced HL. Inotuzumab ozogamicin is a CD22-directed ADC attached to calicheamicin indicated for the treatment of adults with R/R B cell precursor ALL.


Three ADCs have been approved for the treatment of various hematologic malignancies. We discuss the pertinent human trials that led to FDA approval. We include our perspectives about drug resistance, toxicities, and future development.


Antibody-drug conjugate Gemtuzumab ozogamicin Brentuximab vedotin Inotuzumab ozogamicin ADC 


Compliance with Ethical Standards

Conflict of interest

Seattle Genetics: Research support, Consultation, Travel and Speaking engagement.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. 1.
    Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256(5517):495–7.Google Scholar
  2. 2.
    Uhr JW. The 1984 Nobel Prize in medicine. Science. 1984;226(4678):1025–8.PubMedGoogle Scholar
  3. 3.
    Liu AY, et al. Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells. Proc Natl Acad Sci U S A. 1987;84(10):3439–43.PubMedPubMedCentralGoogle Scholar
  4. 4.
    Maloney DG, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood. 1997;90(6):2188–95.Google Scholar
  5. 5.
    Vose JM, et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin’s lymphomas. J Clin Oncol. 2000;18(6):1316–23.PubMedGoogle Scholar
  6. 6.
    Witzig TE, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 1999;17(12):3793–803.PubMedGoogle Scholar
  7. 7.
    Schrama D, Reisfeld RA, Becker JC. Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov. 2006;5(2):147–59.PubMedGoogle Scholar
  8. 8.
    Sievers EL, et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood. 1999;93(11):3678–84.PubMedGoogle Scholar
  9. 9.
    Lee MD, et al. Calichemicins, a novel family of antitumor antibiotics. 1. Chemistry and partial structure of calichemicin.gamma.1I. J Am Chem Soc. 1987;109(11):3464–6.Google Scholar
  10. 10.
    Lee MD, et al. Calicheamicins, a novel family of antitumor antibiotics. 3. Isolation, purification and characterization of calicheamicins beta 1Br, gamma 1Br, alpha 2I, alpha 3I, beta 1I, gamma 1I and delta 1I. J Antibiot (Tokyo). 1989;42(7):1070–87.Google Scholar
  11. 11.
    Dedon PC, Salzberg AA, Xu J. Exclusive production of bistranded DNA damage by calicheamicin. Biochemistry. 1993;32(14):3617–22.PubMedGoogle Scholar
  12. 12.
    Naito K, et al. Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines. Leukemia. 2000;14(8):1436–43.PubMedGoogle Scholar
  13. 13.
    Amico D, et al. Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitro: role of Chk1 and Chk2 phosphorylation and caspase 3. Blood. 2003;101(11):4589–97.PubMedGoogle Scholar
  14. 14.
    Bhattacharyya B, Wolff J. Maytansine binding to the vinblastine sites of tubulin. FEBS Lett. 1977;75(1):159–62.PubMedGoogle Scholar
  15. 15.
    Widdison WC, et al. Semisynthetic maytansine analogues for the targeted treatment of cancer. J Med Chem. 2006;49(14):4392–408.PubMedGoogle Scholar
  16. 16.
    Eaton JS, et al. Ocular adverse events associated with antibody-drug conjugates in human clinical trials. J Ocul Pharmacol Ther. 2015;31(10):589–604.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Pettit GR, et al. The isolation and structure of a remarkable marine animal antineoplastic constituent: dolastatin 10. J Am Chem Soc. 1987;109:6883–5.Google Scholar
  18. 18.
    Doronina SO, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol. 2003;21(7):778–84.PubMedGoogle Scholar
  19. 19.
    Francisco JA, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102(4):1458–65.PubMedGoogle Scholar
  20. 20.
    Goldufsky J, et al. Pseudomonas aeruginosa exotoxin T induces potent cytotoxicity against a variety of murine and human cancer cell lines. J Med Microbiol. 2015;64(Pt 2):164–73.PubMedPubMedCentralGoogle Scholar
  21. 21.
    Weldon JE, Pastan I. A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin a for the treatment of cancer. FEBS J. 2011;278(23):4683–700.PubMedPubMedCentralGoogle Scholar
  22. 22.
    Tendler MD, Korman S. ‘Refuin’: a non-cytotoxic carcinostatic compound proliferated by a thermophilic actinomycete. Nature. 1963;199:501.PubMedGoogle Scholar
  23. 23.
    Leimgruber W, et al. Isolation and characterization of anthramycin, a new antitumor antibiotic. J Am Chem Soc. 1965;87(24):5791–3.PubMedGoogle Scholar
  24. 24.
    Leimgruber W, Batcho AD, Schenker F. The structure of anthramycin. J Am Chem Soc. 1965;87(24):5793–5.PubMedGoogle Scholar
  25. 25.
    Bose DS, et al. Rational design of a highly efficient irreversible DNA interstrand cross-linking agent based on the pyrrolobenzodiazepine ring system. J Am Chem Soc. 1992;114(12):4939–41.Google Scholar
  26. 26.
    Jenkins TC, et al. Structure of a covalent DNA minor groove adduct with a pyrrolobenzodiazepine dimer: evidence for sequence-specific interstrand cross-linking. J Med Chem. 1994;37(26):4529–37.PubMedGoogle Scholar
  27. 27.
    Petrusek RL, et al. Reaction of anthramycin with DNA. Biological consequences of DNA damage in normal and xeroderma pigmentosum cell. J Biol Chem. 1982;257(11):6207–16.PubMedGoogle Scholar
  28. 28.
    Varki A, Angata T. Siglecs--the major subfamily of I-type lectins. Glycobiology. 2006;16(1):1R–27R.PubMedGoogle Scholar
  29. 29.
    Crocker PR, McMillan SJ, Richards HE. CD33-related siglecs as potential modulators of inflammatory responses. Ann N Y Acad Sci. 2012;1253:102–11.PubMedGoogle Scholar
  30. 30.
    Andrews RG, Torok-Storb B, Bernstein ID. Myeloid-associated differentiation antigens on stem cells and their progeny identified by monoclonal antibodies. Blood. 1983;62(1):124–32.PubMedGoogle Scholar
  31. 31.
    Griffin JD, et al. A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leuk Res. 1984;8(4):521–34.PubMedGoogle Scholar
  32. 32.
    Andrews RG, et al. The L4F3 antigen is expressed by unipotent and multipotent colony-forming cells but not by their precursors. Blood. 1986;68(5):1030–5.PubMedGoogle Scholar
  33. 33.
    Andrews RG, Singer JW, Bernstein ID. Precursors of colony-forming cells in humans can be distinguished from colony-forming cells by expression of the CD33 and CD34 antigens and light scatter properties. J Exp Med. 1989;169(5):1721–31.PubMedGoogle Scholar
  34. 34.
    Tanimoto M, et al. Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195. Leukemia. 1989;3(5):339–48.PubMedGoogle Scholar
  35. 35.
    Maniecki MB, et al. Tumor-promoting macrophages induce the expression of the macrophage-specific receptor CD163 in malignant cells. Int J Cancer. 2012;131(10):2320–31.PubMedGoogle Scholar
  36. 36.
    Hernandez-Caselles T, et al. A study of CD33 (SIGLEC-3) antigen expression and function on activated human T and NK cells: two isoforms of CD33 are generated by alternative splicing. J Leukoc Biol. 2006;79(1):46–58.PubMedGoogle Scholar
  37. 37.
    Sievers EL, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001;19(13):3244–54.PubMedGoogle Scholar
  38. 38.
    Hamann PR, et al. An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. Bioconjug Chem. 2002;13(1):40–6.PubMedGoogle Scholar
  39. 39.
    Hamann PR, et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem. 2002;13(1):47–58.PubMedGoogle Scholar
  40. 40.
    Larson RA, et al. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia. 2002;16(9):1627–36.PubMedGoogle Scholar
  41. 41.
    Larson RA, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer. 2005;104(7):1442–52.PubMedGoogle Scholar
  42. 42.
    Petersdorf SH, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013;121(24):4854–60.PubMedPubMedCentralGoogle Scholar
  43. 43.
    Hills RK, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol. 2014;15(9):986–96.PubMedPubMedCentralGoogle Scholar
  44. 44.
    Burnett AK, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol. 2011;29(4):369–77.PubMedGoogle Scholar
  45. 45.
    Castaigne S, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012;379(9825):1508–16.PubMedGoogle Scholar
  46. 46.
    Burnett AK, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol. 2012;30(32):3924–31.PubMedGoogle Scholar
  47. 47.
    Delaunay J, et al. Addition of Gemtuzumab Ozogamycin to chemotherapy improves event-free survival but not overall survival of AML patients with intermediate cytogenetics not eligible for allogeneic transplantation. Results of the GOELAMS AML 2006 IR study. Blood. 2011;118(21):79.Google Scholar
  48. 48.
    Amadori S, et al. Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized phase III EORTC-GIMEMA AML-19 trial. J Clin Oncol. 2016;34(9):972–9.PubMedGoogle Scholar
  49. 49.
    Kartner N, Riordan JR, Ling V. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science. 1983;221(4617):1285–8.PubMedGoogle Scholar
  50. 50.
    Kartner N, et al. Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature. 1985;316(6031):820–3.PubMedGoogle Scholar
  51. 51.
    Matsui H, et al. Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers. Leukemia. 2002;16(5):813–9.PubMedGoogle Scholar
  52. 52.
    Walter RB, et al. Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells. Blood. 2003;102(4):1466–73.PubMedGoogle Scholar
  53. 53.
    Walter RB, et al. CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. Blood. 2007;109(10):4168–70.PubMedPubMedCentralGoogle Scholar
  54. 54.
    Linenberger ML, et al. Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood. 2001;98(4):988–94.PubMedGoogle Scholar
  55. 55.
    Matsumoto T, et al. Importance of inducible multidrug resistance 1 expression in HL-60 cells resistant to gemtuzumab ozogamicin. Leuk Lymphoma. 2012;53(7):1399–405.PubMedGoogle Scholar
  56. 56.
    Apostolidou E, et al. Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia. Leuk Res. 2003;27(10):887–91.PubMedGoogle Scholar
  57. 57.
    Tsimberidou A, et al. Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. Leuk Res. 2003;27(10):893–7.PubMedGoogle Scholar
  58. 58.
    Tsimberidou A, et al. Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes. Cancer. 2003;97(6):1481–7.PubMedGoogle Scholar
  59. 59.
    Walter RB, et al. The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin. Blood. 2004;103(11):4276–84.PubMedGoogle Scholar
  60. 60.
    Walter RB, et al. PK11195, a peripheral benzodiazepine receptor (pBR) ligand, broadly blocks drug efflux to chemosensitize leukemia and myeloma cells by a pBR-independent, direct transporter-modulating mechanism. Blood. 2005;106(10):3584–93.PubMedPubMedCentralGoogle Scholar
  61. 61.
    Kurimoto M, et al. Pretreatment of leukemic cells with low-dose decitabine markedly enhances the cytotoxicity of gemtuzumab ozogamicin. Leukemia. 2013;27(1):233–5.PubMedGoogle Scholar
  62. 62.
    Daver N, et al. A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome. Leukemia. 2016;30(2):268–73.PubMedGoogle Scholar
  63. 63.
    Rosen DB, et al. AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin. PLoS One. 2013;8(1):e53518.PubMedPubMedCentralGoogle Scholar
  64. 64.
    Haag P, et al. Deficient activation of Bak and Bax confers resistance to gemtuzumab ozogamicin-induced apoptotic cell death in AML. Exp Hematol. 2009;37(6):755–66.PubMedGoogle Scholar
  65. 65.
    Giles FJ, et al. Intravenous corticosteroids to reduce gemtuzumab ozogamicin infusion reactions. Ann Pharmacother. 2003;37(9):1182–5.PubMedGoogle Scholar
  66. 66.
    Giles FJ, et al. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer. 2001;92(2):406–13.PubMedGoogle Scholar
  67. 67.
    Wadleigh M, et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood. 2003;102(5):1578–82.PubMedGoogle Scholar
  68. 68.
    Guffroy M, et al. Liver microvascular injury and thrombocytopenia of antibody-calicheamicin conjugates in cynomolgus monkeys-mechanism and monitoring. Clin Cancer Res. 2017;23(7):1760–70.PubMedGoogle Scholar
  69. 69.
    McKoy JM, et al. Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. Leuk Res. 2007;31(5):599–604.PubMedGoogle Scholar
  70. 70.
    Maniecki MB, et al. Is hepatotoxicity in patients treated with gemtuzumabozogamicin due to specific targeting of hepatocytes? Leuk Res. 2011;35(6):e84–6.PubMedGoogle Scholar
  71. 71.
    McDonald GB. Management of hepatic sinusoidal obstruction syndrome following treatment with gemtuzumab ozogamicin (Mylotarg). Clin Lymphoma. 2002;2(Suppl 1):S35–9.PubMedGoogle Scholar
  72. 72.
    Versluys B, et al. Prophylaxis with defibrotide prevents veno-occlusive disease in stem cell transplantation after gemtuzumab ozogamicin exposure. Blood. 2004;103(5):1968.PubMedGoogle Scholar
  73. 73.
    Lannoy D, et al. Gemtuzumab ozogamicin-induced sinusoidal obstructive syndrome treated with defibrotide: a case report. J Clin Pharm Ther. 2006;31(4):389–92.PubMedGoogle Scholar
  74. 74.
    Richardson PG, et al. Defibrotide sodium for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome. Expert Rev Clin Pharmacol. 2018;11(2):113–24.PubMedGoogle Scholar
  75. 75.
    Jawad M, et al. Targeting of CD34+CD38- cells using gemtuzumab ozogamicin (Mylotarg) in combination with tipifarnib (Zarnestra) in acute myeloid Leukaemia. BMC Cancer. 2012;12:431.PubMedPubMedCentralGoogle Scholar
  76. 76.
    Rosen DB, et al. Assessing signaling pathways associated with in vitro resistance to cytotoxic agents in AML. Leuk Res. 2012;36(7):900–4.PubMedGoogle Scholar
  77. 77.
    Lapusan S, et al. Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia. Investig New Drugs. 2012;30(3):1121–31.Google Scholar
  78. 78.
    Kung Sutherland MS, et al. SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood. 2013;122(8):1455–63.PubMedGoogle Scholar
  79. 79.
    Stein EM, et al. A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia. Blood. 2018;131(4):387–96.PubMedPubMedCentralGoogle Scholar
  80. 80.
    Stein H, et al. Identification of Hodgkin and Sternberg-reed cells as a unique cell type derived from a newly-detected small-cell population. Int J Cancer. 1982;30(4):445–59.PubMedGoogle Scholar
  81. 81.
    Durkop H, et al. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin’s disease. Cell. 1992;68(3):421–7.PubMedGoogle Scholar
  82. 82.
    Schwab U, et al. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin’s disease and a subset of normal lymphoid cells. Nature. 1982;299(5878):65–7.PubMedGoogle Scholar
  83. 83.
    Ellis TM, et al. CD30 is a signal-transducing molecule that defines a subset of human activated CD45RO+ T cells. J Immunol. 1993;151(5):2380–9.PubMedGoogle Scholar
  84. 84.
    Stein H, et al. Hodgkin and Sternberg-reed cells contain antigens specific to late cells of granulopoiesis. Int J Cancer. 1982;29(3):283–90.PubMedGoogle Scholar
  85. 85.
    Feller AC, Sterry W. Large cell anaplastic lymphoma of the skin. Br J Dermatol. 1989;121(5):593–602.PubMedGoogle Scholar
  86. 86.
    Hu S, et al. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the international DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2013;121(14):2715–24.PubMedPubMedCentralGoogle Scholar
  87. 87.
    Kaudewitz P, et al. Monoclonal antibody patterns in lymphomatoid papulosis. Dermatol Clin. 1985;3(4):749–57.PubMedGoogle Scholar
  88. 88.
    Blatt K, et al. Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis. Blood. 2015;126(26):2832–41.PubMedPubMedCentralGoogle Scholar
  89. 89.
    Gerli R, et al. CD30+ T cells in rheumatoid synovitis: mechanisms of recruitment and functional role. J Immunol. 2000;164(8):4399–407.PubMedGoogle Scholar
  90. 90.
    Ihn H, et al. Circulating levels of soluble CD30 are increased in patients with localized scleroderma and correlated with serological and clinical features of the disease. J Rheumatol. 2000;27(3):698–702.PubMedGoogle Scholar
  91. 91.
    McMillan SA, et al. Evaluation of the clinical utility of cerebrospinal fluid (CSF) indices of inflammatory markers in multiple sclerosis. Acta Neurol Scand. 2000;101(4):239–43.PubMedGoogle Scholar
  92. 92.
    Barbieri A, et al. Characterization of CD30/CD30L(+) cells in peripheral blood and synovial fluid of patients with rheumatoid arthritis. J Immunol Res. 2015;2015:729654.PubMedPubMedCentralGoogle Scholar
  93. 93.
    Shinoda K, et al. Requirement of CD30 expression on CD4 T cells in the pathogenesis of experimental autoimmune encephalomyelitis. J Neuroimmunol. 2016;291:39–45.PubMedGoogle Scholar
  94. 94.
    Gerli R, et al. Role of CD30+ T cells in rheumatoid arthritis: a counter-regulatory paradigm for Th1-driven diseases. Trends Immunol. 2001;22(2):72–7.PubMedGoogle Scholar
  95. 95.
    Younes A, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363(19):1812–21.PubMedGoogle Scholar
  96. 96.
    •• Younes A, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30(18):2183–9 This important trial studied Bv in R/R HL patients who failed autoSCT and contributed to the FDA approval of Bv for R/R HL.PubMedPubMedCentralGoogle Scholar
  97. 97.
    Chen R, et al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2016;128(12):1562–6.PubMedPubMedCentralGoogle Scholar
  98. 98.
    Pro B, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30(18):2190–6.PubMedGoogle Scholar
  99. 99.
    Moskowitz CH, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385(9980):1853–62.PubMedGoogle Scholar
  100. 100.
    Younes A, et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin’s lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol. 2013;14(13):1348–56.PubMedGoogle Scholar
  101. 101.
    Connors JM, et al. Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma. Blood. 2017;130(11):1375–7.PubMedPubMedCentralGoogle Scholar
  102. 102.
    Connors JM, et al. Brentuximab Vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma. N Engl J Med. 2018;378(4):331–44.PubMedGoogle Scholar
  103. 103.
    LaCasce AS, et al. Brentuximab vedotin plus bendamustine: a highly active salvage treatment regimen for patients with relapsed or refractory Hodgkin lymphoma. Blood. 2015;126(23):3982.Google Scholar
  104. 104.
    O’Connor OA, et al. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin’s lymphoma: an international, multicentre, single-arm, phase 1-2 trial. Lancet Oncol. 2018;19(2):257–66.PubMedGoogle Scholar
  105. 105.
    Horwitz SM, et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood. 2014;123(20):3095–100.PubMedPubMedCentralGoogle Scholar
  106. 106.
    Mehra T, et al. Brentuximab as a treatment for CD30+ mycosis fungoides and Sezary syndrome. JAMA Dermatol. 2015;151(1):73–7.PubMedGoogle Scholar
  107. 107.
    Kim YH, et al. Phase II investigator-initiated study of Brentuximab Vedotin in mycosis Fungoides and Sezary syndrome with variable CD30 expression level: a multi-institution collaborative project. J Clin Oncol. 2015;33(32):3750–8.PubMedPubMedCentralGoogle Scholar
  108. 108.
    Duvic M, et al. Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis. J Clin Oncol. 2015;33(32):3759–65.PubMedPubMedCentralGoogle Scholar
  109. 109.
    Prince HM, et al. Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017;390(10094):555–66.PubMedGoogle Scholar
  110. 110.
    Jacobsen ED, et al. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood. 2015;125(9):1394–402.PubMedGoogle Scholar
  111. 111.
    DeFilipp Z, et al. Phase I trial of brentuximab vedotin for steroid-refractory chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2018.Google Scholar
  112. 112.
    Chen R, et al. CD30 downregulation, MMAE resistance, and MDR1 upregulation are all associated with resistance to brentuximab vedotin. Mol Cancer Ther. 2015;14(6):1376–84.PubMedPubMedCentralGoogle Scholar
  113. 113.
    Straus DJ et al. Improving outcomes with brentuximab vedotin (BV) plus chemotherapy in patients with newly diagnosed advanced stage Hodgkin lymphoma. J Clin Oncol. 2018;36(Suppl).Google Scholar
  114. 114.
    Hershman DL, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32(18):1941–67.PubMedGoogle Scholar
  115. 115.
    Jalan P, et al. Brentuximab associated progressive multifocal leukoencephalopathy. Clin Neurol Neurosurg. 2012;114(10):1335–7.PubMedGoogle Scholar
  116. 116.
    Urru SA, et al. Acute pancreatitis following brentuximab vedotin therapy for refractory Hodgkin lymphoma: a case report. Drugs R D. 2014;14(1):9–11.PubMedPubMedCentralGoogle Scholar
  117. 117.
    Carson KR, et al. Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project. Cancer. 2014;120(16):2464–71.PubMedPubMedCentralGoogle Scholar
  118. 118.
    Gandhi MD, et al. Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event. Blood. 2014;123(18):2895–7.PubMedPubMedCentralGoogle Scholar
  119. 119.
    Diefenbach CS, et al. Safety and efficacy of combination of brentuximab vedotin and Nivolumab in relapsed/refractory Hodgkin lymphoma: a trial of the ECOG-ACRIN Cancer research group (E4412). Hematol Oncol. 2017;128(22):1106.Google Scholar
  120. 120.
    Herrera AF, et al. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2018;131(11):1183–94.PubMedPubMedCentralGoogle Scholar
  121. 121.
    Doody GM, et al. A role in B cell activation for CD22 and the protein tyrosine phosphatase SHP. Science. 1995;269(5221):242–4.PubMedGoogle Scholar
  122. 122.
    Nitschke L. CD22 and Siglec-G: B-cell inhibitory receptors with distinct functions. Immunol Rev. 2009;230(1):128–43.PubMedGoogle Scholar
  123. 123.
    Vaickus L, Ball ED, Foon KA. Immune markers in hematologic malignancies. Crit Rev Oncol Hematol. 1991;11(4):267–97.PubMedGoogle Scholar
  124. 124.
    Raponi S, et al. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leuk Lymphoma. 2011;52(6):1098–107.PubMedGoogle Scholar
  125. 125.
    Piccaluga PP, et al. Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia. Leuk Lymphoma. 2011;52(2):325–7.PubMedGoogle Scholar
  126. 126.
    Shan D, Press OW. Constitutive endocytosis and degradation of CD22 by human B cells. J Immunol. 1995;154(9):4466–75.PubMedGoogle Scholar
  127. 127.
    DiJoseph JF, et al. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood. 2004;103(5):1807–14.PubMedGoogle Scholar
  128. 128.
    Advani A, et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin’s lymphoma: results of a phase I study. J Clin Oncol. 2010;28(12):2085–93.PubMedGoogle Scholar
  129. 129.
    Ogura M, et al. Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy. Cancer Sci. 2010;101(8):1840–5.PubMedGoogle Scholar
  130. 130.
    Goy A, et al. A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy. Br J Haematol. 2016;174(4):571–81.PubMedGoogle Scholar
  131. 131.
    Ogura M, et al. Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma. Cancer Sci. 2012;103(5):933–8.PubMedGoogle Scholar
  132. 132.
    Fayad L, et al. Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. J Clin Oncol. 2013;31(5):573–83.PubMedPubMedCentralGoogle Scholar
  133. 133.
    Takeshita A, et al. CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells. Leukemia. 2009;23(7):1329–36.PubMedGoogle Scholar
  134. 134.
    Wagner-Johnston ND, et al. A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma. Leuk Lymphoma. 2015;56(10):2863–9.PubMedGoogle Scholar
  135. 135.
    Ogura M, et al. Phase I study of inotuzumab ozogamicin combined with R-CVP for relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma. Clin Cancer Res. 2016;22(19):4807–16.PubMedGoogle Scholar
  136. 136.
    Sangha R, et al. Phase 1 study of inotuzumab ozogamicin combined with R-GDP for the treatment of patients with relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma. J Drug Assess. 2017;6(1):10–7.PubMedPubMedCentralGoogle Scholar
  137. 137.
    Dang NH, et al. Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Br J Haematol. 2017.Google Scholar
  138. 138.
    •• Kantarjian H, et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012;13(4):403–11 This important phase II trial led to promising results in B-ALL, contributing to the basis for FDA approval in a disease where there are limited options after relapse.PubMedGoogle Scholar
  139. 139.
    Kantarjian H, et al. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013;119(15):2728–36.PubMedPubMedCentralGoogle Scholar
  140. 140.
    DeAngelo DJ, et al. Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study. Blood Adv. 2017;1(15):1167–80.PubMedPubMedCentralGoogle Scholar
  141. 141.
    Kantarjian HM, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375(8):740–53.PubMedPubMedCentralGoogle Scholar
  142. 142.
    Jabbour E, et al. Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody. Am J Hematol. 2015;90(3):193–6.PubMedPubMedCentralGoogle Scholar
  143. 143.
    Kantarjian H, et al. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2018;19(2):240–8.PubMedGoogle Scholar
  144. 144.
    Stephan JP, et al. Anti-CD22-MCC-DM1 and MC-MMAF conjugates: impact of assay format on pharmacokinetic parameters determination. Bioconjug Chem. 2008;19(8):1673–83.PubMedGoogle Scholar
  145. 145.
    Polson AG, et al. Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin’s lymphoma. Leukemia. 2010;24(9):1566–73.PubMedGoogle Scholar
  146. 146.
    Kato J, et al. Efficacy and toxicity of a CD22-targeted antibody-saporin conjugate in a xenograft model of non-Hodgkin’s lymphoma. Oncoimmunology. 2012;1(9):1469–75.PubMedPubMedCentralGoogle Scholar
  147. 147.
    Kato J, et al. Efficacy of a CD22-targeted antibody-saporin conjugate in a xenograft model of precursor-B cell acute lymphoblastic leukemia. Leuk Res. 2013;37(1):83–8.PubMedGoogle Scholar
  148. 148.
    Takeshita A, et al. CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma. Br J Haematol. 2009;146(1):34–43.PubMedGoogle Scholar
  149. 149.
    Kebriaei P, et al. Management of important adverse events associated with inotuzumab ozogamicin: expert panel review. Bone Marrow Transplant. 2018;53(4):449–56.PubMedPubMedCentralGoogle Scholar
  150. 150.
    Li D, et al. DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma. Mol Cancer Ther. 2013;12(7):1255–65.PubMedGoogle Scholar
  151. 151.
    Fuh FK, et al. Anti-CD22 and anti-CD79b antibody-drug conjugates preferentially target proliferating B cells. Br J Pharmacol. 2017;174(8):628–40.PubMedPubMedCentralGoogle Scholar
  152. 152.
    Abuhay M, et al. The HB22.7-vcMMAE antibody-drug conjugate has efficacy against non-Hodgkin lymphoma mouse xenografts with minimal systemic toxicity. Cancer Immunol Immunother. 2016;65(10):1169–75.PubMedGoogle Scholar
  153. 153.
    Kantarjian HM, et al. Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia. Cancer. 2018;124(10):2151–60.PubMedGoogle Scholar
  154. 154.
    Kreitman RJ, et al. Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up. Blood. 2018;131(21):2331–4.PubMedGoogle Scholar
  155. 155.
    Kreitman RJ, et al. Moxetumomab pasudotox in heavily pretreated patients with relapsed/refractory hairy cell leukemia: results of a pivotal international study. J Clin Oncol. 2018;36.Google Scholar
  156. 156.
    Advani RH, et al. Phase I study of the anti-CD22 antibody-drug conjugate pinatuzumab vedotin with/without rituximab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res. 2017;23(5):1167–76.PubMedGoogle Scholar
  157. 157.
    Morschhauser F, et al. Updated results of a phase II randomized study (ROMULUS) of polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed/refractory non-Hodgkin lymphoma. Blood. 2014;124(21):4457.Google Scholar
  158. 158.
    Trneny M, et al. A phase 2 multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy. Haematologica. 2018.Google Scholar
  159. 159.
    Kahl BS, et al. Encouraging early results from the first in-human clinical trial of ADCT-402 (loncastuximab tesirine), a novel pyrrolobenzodiazepine-based antibody drug conjugate, in relapsed/refractory B-cell lineage non-Hodgkin lymphoma. Blood. 2017;130(Suppl 1):187.Google Scholar
  160. 160.
    Ryan MC, et al. Therapeutic potential of SGN-CD19B, a PBD-based anti-CD19 drug conjugate, for treatment of B-cell malignancies. Blood. 2017;130(18):2018–26.PubMedPubMedCentralGoogle Scholar
  161. 161.
    Horwitz SM, et al. Interim results from a phase 1 study of ADCT-301 (camidanlumab tesirine) show promising activity of a novel Pyrrolobenzodiazepine-based antibody drug conjugate in relapsed/refractory Hodgkin/non-Hodgkin lymphoma. Blood. 2018;130(Suppl 1):1510.Google Scholar
  162. 162.
    Sawas A, et al. A first in human experience of the anti-CD37 antibody-drug conjugate AGS67E in lymphoid malignancies. J Clin Oncol. 2016;34(15_suppl):7549.Google Scholar
  163. 163.
    Stathis A, et al. Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study. Investig New Drugs. 2018:1–8.Google Scholar
  164. 164.
    Kelly KR, et al. Indatuximab Ravtansine (BT062) in combination with low-dose dexamethasone and lenalidomide or pomalidomide: clinical activity in patients with relapsed/refractory multiple myeloma. Blood. 2016;128(22):4486.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Columbia University Medical CenterNew YorkUSA

Personalised recommendations